Dimensional Fund Advisors LP Boosts Holdings in Oric Pharmaceuticals, Inc. $ORIC

Key Points

• Dimensional Fund Advisors increased its Oric Pharmaceuticals stake by 19.9% in the first quarter, bringing its holdings to 1.47 million shares worth approximately $18.6 million. Institutional investors collectively own 95.05% of the company.
• Analyst sentiment is largely positive: 13 analysts rate ORIC a Buy, with an average target price of $19.27. Goldman Sachs upgraded the stock to Buy, while other firms maintained bullish ratings.
• ORIC traded up 4.4% to $13.50, but the company reported a quarterly loss of $0.38 per share, slightly worse than the $0.36 consensus estimate. Analysts expect a full-year loss of $1.49 per share.

Dimensional Fund Advisors LP increased its holdings in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 19.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,471,290 shares of the company's stock after acquiring an additional 244,060 shares during the quarter. Dimensional Fund Advisors LP owned about 1.42% of Oric Pharmaceuticals worth $18,637,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. AQR Capital Management LLC acquired a new position in Oric Pharmaceuticals in the first quarter valued at about $276,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Oric Pharmaceuticals by 8.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company's stock worth $226,000 after buying an additional 3,131 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Oric Pharmaceuticals by 9.2% during the first quarter. Goldman Sachs Group Inc. now owns 294,784 shares of the company's stock worth $1,645,000 after acquiring an additional 24,778 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Oric Pharmaceuticals by 1,331.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company's stock valued at $2,841,000 after purchasing an additional 473,600 shares during the period. Finally, Jane Street Group LLC increased its stake in Oric Pharmaceuticals by 56.0% in the 1st quarter. Jane Street Group LLC now owns 31,198 shares of the company's stock valued at $174,000 after buying an additional 11,198 shares during the period. Institutional investors and hedge funds own 95.05% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. The Goldman Sachs Group upgraded shares of Oric Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $15.00 target price on the stock in a research report on Friday, May 15th. Stifel Nicolaus started coverage on shares of Oric Pharmaceuticals in a research note on Friday, June 12th. They set a "buy" rating and a $14.00 price target on the stock. Benchmark reiterated a "buy" rating on shares of Oric Pharmaceuticals in a report on Monday, June 8th. Cantor Fitzgerald reissued an "overweight" rating on shares of Oric Pharmaceuticals in a research report on Friday, May 22nd. Finally, Citigroup reduced their price objective on shares of Oric Pharmaceuticals from $17.00 to $16.00 and set a "buy" rating on the stock in a research note on Tuesday, May 5th. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $19.27.

Oric Pharmaceuticals Trading Up 4.4%

Oric Pharmaceuticals stock opened at $13.50 on Friday. Oric Pharmaceuticals, Inc. has a 52 week low of $7.23 and a 52 week high of $14.93. The stock has a market cap of $1.40 billion, a P/E ratio of -10.00 and a beta of 1.02. The stock has a 50 day moving average of $10.15 and a 200-day moving average of $10.47.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.02). As a group, equities analysts predict that Oric Pharmaceuticals, Inc. will post -1.49 earnings per share for the current fiscal year.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company's pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source